Patent Office Awards Patent Term Adjustment Based on Delay Related to a Vacated Office Action
Firm News, Patent
Meunier Carlin & Curfman client Oncolytics Biotech Inc. of Calgary, Alberta, Canada, the assignee of US Patent No. 7,803,385 directed to a modified reovirus for the treatment of cancer, finally received a Certificate of Correction from the US Patent and Trademark Office (USPTO) showing 122 days of patent term adjustment, a patent term adjustment originally and repeatedly denied by the USPTO.